These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26926233)

  • 21. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
    Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
    Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroimaging-Aided Prediction of the Effect of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder: A Randomized Controlled Trial.
    Ishii-Takahashi A; Takizawa R; Nishimura Y; Kawakubo Y; Hamada K; Okuhata S; Kawasaki S; Kuwabara H; Shimada T; Todokoro A; Igarashi T; Watanabe K; Yamasue H; Kato N; Kasai K; Kano Y
    Neuropsychopharmacology; 2015 Nov; 40(12):2676-85. PubMed ID: 25936640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of osmotic-release methylphenidate in attention-deficit/hyperactivity disorder as measured by event-related potentials.
    Sawada M; Iida J; Ota T; Negoro H; Tanaka S; Sadamatsu M; Kishimoto T
    Psychiatry Clin Neurosci; 2010 Oct; 64(5):491-8. PubMed ID: 20923428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to methylphenidate in children with ADHD and comorbid anxiety.
    Diamond IR; Tannock R; Schachar RJ
    J Am Acad Child Adolesc Psychiatry; 1999 Apr; 38(4):402-9. PubMed ID: 10199111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced salivary cortisol in children with comorbid Attention deficit hyperactivity disorder and oppositional defiant disorder.
    Kariyawasam SH; Zaw F; Handley SL
    Neuro Endocrinol Lett; 2002 Feb; 23(1):45-8. PubMed ID: 11880861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial.
    Golubchik P; Sever J; Zalsman G; Weizman A
    Int Clin Psychopharmacol; 2008 Jul; 23(4):228-31. PubMed ID: 18446088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective follow-up studies found no chromosomal mutagenicity of methylphenidate therapy in ADHD affected children.
    Walitza S; Kämpf K; Oli RG; Warnke A; Gerlach M; Stopper H
    Toxicol Lett; 2010 Mar; 193(1):4-8. PubMed ID: 20026394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task.
    Rubia K; Halari R; Cubillo A; Mohammad AM; Brammer M; Taylor E
    Neuropharmacology; 2009 Dec; 57(7-8):640-52. PubMed ID: 19715709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.
    Casas M; Rösler M; Sandra Kooij JJ; Ginsberg Y; Ramos-Quiroga JA; Heger S; Berwaerts J; Dejonckheere J; van der Vorst E; Schäuble B
    World J Biol Psychiatry; 2013 May; 14(4):268-81. PubMed ID: 22106853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of methylphenidate in ADHD adults on target evaluation processing reflected by event-related potentials.
    Ohlmeier MD; Prox V; Zhang Y; Zedler M; Ziegenbein M; Emrich HM; Dietrich DE
    Neurosci Lett; 2007 Sep; 424(3):149-54. PubMed ID: 17723273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder.
    Bellgrove MA; Hawi Z; Kirley A; Fitzgerald M; Gill M; Robertson IH
    Neuropsychopharmacology; 2005 Dec; 30(12):2290-7. PubMed ID: 16123773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The diagnostic evaluation and therapeutic basis of immediate release methylphenidate in attention deficit hyperactivity disorder].
    Valdizán JR
    Rev Neurol; 2004 Mar 16-31; 38(6):501-6. PubMed ID: 15054710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder?
    Walitza S; Werner B; Romanos M; Warnke A; Gerlach M; Stopper H
    Environ Health Perspect; 2007 Jun; 115(6):936-40. PubMed ID: 17589603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of methylphenidate on sustained attention among adolescents with attention-deficit hyperactivity disorder.
    Lufi D; Bassin-Savion S; Rubel L
    Neurocase; 2015; 21(6):802-8. PubMed ID: 25771849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting methylphenidate response in attention deficit hyperactivity disorder: a preliminary study.
    Johnston BA; Coghill D; Matthews K; Steele JD
    J Psychopharmacol; 2015 Jan; 29(1):24-30. PubMed ID: 25237119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy.
    Palumbo D; Spencer T; Lynch J; Co-Chien H; Faraone SV
    J Child Adolesc Psychopharmacol; 2004; 14(2):185-94. PubMed ID: 15319016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylphenidate-related growth impairment.
    Holtkamp K; Peters-Wallraf B; Wüller S; Pfäaffle R; Herpertz-Dahlmann B
    J Child Adolesc Psychopharmacol; 2002; 12(1):55-61. PubMed ID: 12014596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.